Retour aux projets

16405.1 PFLS-LS

16405.1 PFLS-LS

Résumé

Translational studies of fistulizing Crohn's disease in patient samples and mouse models to support the development of a novel therapy.

Textes supplémentaires

Abstract

|Calypso Biotech SA is developing a new therapeutic antibody, CALY-001, for fistulizing Crohn's disease (FCD), a severe disease poorly addressed by current treatments. The project aims at 1) identifying biomarkers of fistula formation and CALY-001 activity with the potential to aid in diagnosis and management of FCD and 2) testing efficacy of CALY-001 in relevant experimental models.

Participants

Yolande Chvatchko

Wirtschaftspartner

yolande.chvatchko@calypsobiotech.com

Calypso Biotech SA Yolande Chvatchko Chemin des Aulx, 14 1228 Plan-les-Ouates GE CH

Gerhard Rogler

Kontaktperson

gerhard.rogler@usz.ch

USZ Universitätsspital Zürich Gerhard Rogler Rämistrasse 100 8091 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2014-05-31
Date de fin
2015-09-30
Coûts totaux approuvés
CHF 186072.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%